817-329-0626 Body Piercing Saved My Life

How medication-assisted treatment reduces relapse rates

For people with opioid dependence, medication-assisted treatment (MAT) can replace repeated cycles of withdrawal, craving and relapse with greater stability. Methadone and buprenorphine are the main evidence-based medicines for opioid use disorder in Australia. They reduce withdrawal and cravings without the usual intoxication of illicit opioids, while lowering the overdose risk linked to repeated use.

No single relapse percentage applies to everyone. Outcomes depend on the medicine, dose, continuity of care, physical and mental health, housing and support. The evidence favours sustained access to medication and respectful, non-stigmatising care rather than a short detox followed by unsupported abstinence.

Treatment options at a glance

Option Main role Relapse-related benefit Important considerations
Methadone Opioid dependence Suppresses withdrawal and craving and supports treatment retention Requires an authorised program; combining it with alcohol or sedatives increases overdose risk
Buprenorphine Opioid dependence Suppresses withdrawal and craving with lower misuse potential than full opioid agonists Starting it needs clinical guidance; prescribing rules vary by state
Naltrexone Alcohol dependence Can reduce heavy drinking and craving Must be started when opioid-free; medical review is needed
Acamprosate Alcohol dependence Helps reduce craving and maintain abstinence Kidney function and regular dosing need review
Disulfiram Alcohol dependence Creates an unpleasant reaction if alcohol is consumed, supporting abstinence in selected people Medical supervision is needed; it does not reduce craving

Medication choice is not a ranking contest. Methadone and buprenorphine address withdrawal and craving directly, while alcohol medicines use different pathways. Choice should reflect medical history, pregnancy, goals and the level of support available.

Detoxification alone carries a high relapse risk because tolerance falls quickly. A supported transition to methadone or buprenorphine is generally more protective than completing withdrawal unsupported. Medication can be paired with counselling, peer support, harm reduction and treatment for co-occurring conditions.

Why medication lowers relapse risk

Cravings can become overwhelming when withdrawal is severe, sleep is poor or a familiar trigger appears. Stable medication reduces the physiological urgency to use, allowing a person to make decisions that would be difficult while managing untreated withdrawal. Continuity of dosing therefore matters as much as the initial prescription.

Relapse after abstinence can be more dangerous because tolerance has fallen. Naloxone, avoiding use alone and prompt emergency care reduce harm if someone overdoses. A resource offering harm reduction guidance may help with planning, but local clinical advice and emergency services remain essential.

Medication does not remove every trigger or guarantee lifelong recovery. It creates physiological stability while a person rebuilds relationships, work and daily routines. If medication is stopped or a dose is missed, a clinician can review the plan without treating the person as a failure.

Access and supports across Australia

Australian opioid treatment is delivered through opioid treatment programs, community pharmacies and, in some settings, GPs. Many services use opioid agonist therapy rather than MAT. Methadone is generally provided through an authorised program; buprenorphine may be prescribed by a GP and dispensed through a pharmacy under state rules. PBS subsidies and TGA approval help determine cost, supply and approved options.

In Melbourne, Sydney, Brisbane, Perth and Adelaide, public hospitals, specialist alcohol and other drug services and pharmacies create several routes into care, although waiting lists and opening hours vary. Access plans can also address transport, disability and vision needs; someone who relies on corrective lenses can compare everyday eyewear options while arranging appointments and reading dosing instructions.

Outside major cities, travel and limited pharmacy access can interrupt treatment. Aboriginal community-controlled services and Aboriginal medical services in regional and remote areas, including northern Australia, can offer culturally safe pathways into care. Telehealth, take-home dosing where permitted and local naloxone programs can reduce gaps; the National Alcohol and Other Drug Hotline on 1800 250 000 provides free, confidential information.

Alcohol and social pressures

Alcohol dependence calls for a different medication discussion. Naltrexone can reduce heavy drinking, acamprosate can reduce craving and support abstinence, and disulfiram creates an unpleasant reaction if alcohol is consumed. None replaces medical review, addiction support or a plan for high-risk situations. The TGA has not approved a medicine specifically for stimulant use disorder, so behavioural treatment and harm reduction remain central.

Australian drinking customs often connect alcohol with pubs, clubs, BYO venues, weddings, work functions and sporting events. Refusing a drink can feel conspicuous when changing a long-standing routine. Planning a meal, identifying a trusted friend and choosing an early exit can help; an article on social situations without alcohol offers a practical starting point for those conversations.

Social support can protect recovery or add pressure. Friends who drink heavily may require new boundaries, while a sport, cultural group, faith community or peer group can provide connection without substances. Care that respects a person’s culture, gender, sexuality and working conditions can make these alternatives more durable.

Making recovery sustainable

A relapse-prevention plan should be usable on a difficult day: where the next dose is collected, who holds spare naloxone, which triggers need another route and which clinician to call. For someone unsure how to approach a clinic, a support contact page can provide a low-pressure place to ask what services exist, whether an appointment is needed and how privacy is handled.

Good treatment also addresses sleep, mental health, chronic pain, hepatitis C, dental problems and housing instability. These practical issues often determine whether people continue attending medication and other appointments. A relapse can prompt a review of the plan, rather than proving recovery has failed or the person lacks willpower.

When medication is accessible, individualised and paired with respect, it replaces a constant cycle of craving and risky use with the stability needed to build a safer, more connected life.